K Pharma

K Pharma EBIT per Share

The EBIT per Share of K Pharma (4896.T) as of Oct 17, 2026 is -78.93 JPY. In the previous year, EBIT per Share was -72.07 JPY — a change of 9.52% (lower).

EBIT per Share

-78.93JPY

YoY

9.52%

Last updated:

EBIT per Share of K Pharma is 2025 -78.93 JPY. EBIT per Share of K Pharma was 2024 -72.07 JPY. It decreases by 9.52% lower compared to the previous year.

The K Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
-18.88 JPY
Jan 1, 2022
-30.44 JPY
Jan 1, 2023
39.23 JPY
Jan 1, 2024
-72.07 JPY
Jan 1, 2025
-78.93 JPY
Jan 1, 2026 (e)
0.00 JPY
The K Pharma EBIT per Share history
YEAREBIT per ShareYoY
est0.00JPY-100.00%
-78.93JPY+9.52%
-72.07JPY-283.71%
39.23JPY-228.89%
-30.44JPY+61.18%
-18.88JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc is a Japan-based pharmaceutical company headquartered in Minato-ku, Tokyo. The company operates in the Health Care sector, specifically within the Pharmaceuticals industry. It has a small team of 13 full-time employees. K Pharma Inc completed its initial public offering (IPO) on October 17, 2023, with the ticker symbol 4896.T and ISIN JP3280900006. The company's website is https://kpharma.co.jp/. K Pharma Inc focuses on the research, development, manufacture, and sale of pharmaceuticals. It is engaged in the field of induced pluripotent stem cell (iPS) drug discovery, which involves creating neural progenitor cells from iPS cells. These cells are cryopreserved and used in a treatment process where 200,000 cells are transplanted via injection into the spinal cord injury site of patients. The company also conducts research, development, manufacture, and sale of regenerative medicine products. K Pharma Inc operates through a single business segment, concentrating on pharmaceutical and regenerative medicine solutions. The company's activities are centered on developing innovative treatments, particularly in the area of spinal cord injury recovery using stem cell technology. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

EBIT per Share of K Pharma is -78.93 JPY in 2025.

EBIT per Share of K Pharma changed from -72.07 JPY to -78.93 JPY, representing a 9.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share K Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — K Pharma

All Key Metrics — K Pharma